Menarini Stemline: the ambition of the first Italian laboratory in the fight against cancer

Responding to the biggest public health challenges A subsidiary of the Menarini group which is today among the world leaders in health, Menarini Stemline embodies the commitment of the Italian pharmaceutical laboratory in the fight against cancer. “Our commitment focuses on therapeutic areas with high unmet medical needs. Menarini's products meet the needs of patients in areas such as cardiovascular diseases, respiratory diseases and, through Menarini Stemline, oncology.

These are the three main causes of mortality in France and around the world,” explains Stéphane Lomenède, General Manager France & Benelux at Menarini Stemline. The acquisition of Stemline Therapeutics Under the leadership of its general director Elcin Barker Ergun, who arrived in 2019, the Menarini group achieved two major objectives by establishing itself in the United States and entering the global oncology market. “This strategy materialized through the acquisition of Stemline Therapeutics, a biotechnology company founded in 2003.

At the time of its acquisition, the American biotech already marketed the only treatment approved by the FDA against a rare and aggressive blood cancer. » As Stéphane Lomenède points out, this merger is based on a common culture of innovation and a firm commitment: that of developing new drugs that meet important and unmet medical needs for the direct benefit of patients. Investments and R&D: France at the heart of the European system Menarini relies on a strong European anchor on a daily basis, with two thirds of its R&D centers and production sites based in the EU.

Present in France since 1992, the Menarini group generates 600 direct and 3,000 indirect jobs. Its oncology subsidiary created in France in 2022, Menarini Stemline, is investing 35 to 40 million euros over five years to conduct 13 clinical trials in hematological cancers and solid tumors, mainly female cancers. The active ingredient of one of its anti-cancer drugs is produced in Isère for the global market and the laboratory has decided to also set up the production line for another of its anti-cancer drugs there for the European market.

For more information, go to the Menarini Stemline website. The BFM Business editorial team did not participate in the production of this content in partnership with OpenMedias.

Machine-translated from French